GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioLine Rx Ltd (NAS:BLRX) » Definitions » Cyclically Adjusted PB Ratio

BioLine Rx (BioLine Rx) Cyclically Adjusted PB Ratio : 0.08 (As of May. 16, 2024)


View and export this data going back to 2011. Start your Free Trial

What is BioLine Rx Cyclically Adjusted PB Ratio?

As of today (2024-05-16), BioLine Rx's current share price is $0.6371. BioLine Rx's Cyclically Adjusted Book per Share for the quarter that ended in Dec. 2023 was $7.69. BioLine Rx's Cyclically Adjusted PB Ratio for today is 0.08.

The historical rank and industry rank for BioLine Rx's Cyclically Adjusted PB Ratio or its related term are showing as below:

BLRX' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 0.08   Med: 0.15   Max: 0.2
Current: 0.09

During the past years, BioLine Rx's highest Cyclically Adjusted PB Ratio was 0.20. The lowest was 0.08. And the median was 0.15.

BLRX's Cyclically Adjusted PB Ratio is ranked better than
89.94% of 646 companies
in the Biotechnology industry
Industry Median: 1.76 vs BLRX: 0.09

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

BioLine Rx's adjusted book value per share data for the three months ended in Dec. 2023 was $0.183. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $7.69 for the trailing ten years ended in Dec. 2023.

Shiller PE for Stocks: The True Measure of Stock Valuation


BioLine Rx Cyclically Adjusted PB Ratio Historical Data

The historical data trend for BioLine Rx's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioLine Rx Cyclically Adjusted PB Ratio Chart

BioLine Rx Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.15 0.17 0.17 0.07 0.20

BioLine Rx Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.07 0.10 0.20 0.25 0.20

Competitive Comparison of BioLine Rx's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, BioLine Rx's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BioLine Rx's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BioLine Rx's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where BioLine Rx's Cyclically Adjusted PB Ratio falls into.



BioLine Rx Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

BioLine Rx's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=0.6371/7.69
=0.08

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BioLine Rx's Cyclically Adjusted Book per Share for the quarter that ended in Dec. 2023 is calculated as:

For example, BioLine Rx's adjusted Book Value per Share data for the three months ended in Dec. 2023 was:

Adj_Book=Book Value per Share/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=0.183/129.4194*129.4194
=0.183

Current CPI (Dec. 2023) = 129.4194.

BioLine Rx Quarterly Data

Book Value per Share CPI Adj_Book
201403 14.269 99.695 18.523
201406 12.876 100.560 16.571
201409 11.812 100.428 15.222
201412 12.197 99.070 15.934
201503 15.196 99.621 19.741
201506 14.531 100.684 18.678
201509 13.908 100.392 17.929
201512 13.028 99.792 16.896
201603 12.229 100.470 15.753
201606 11.315 101.688 14.401
201609 10.262 101.861 13.038
201612 9.212 101.863 11.704
201703 8.671 102.862 10.910
201706 9.009 103.349 11.282
201709 8.504 104.136 10.569
201712 7.550 104.011 9.394
201803 6.912 105.290 8.496
201806 6.413 106.317 7.807
201809 5.632 106.507 6.844
201812 5.393 105.998 6.585
201903 4.761 107.251 5.745
201906 4.258 108.070 5.099
201909 3.876 108.329 4.631
201912 2.923 108.420 3.489
202003 2.393 108.902 2.844
202006 1.479 108.767 1.760
202009 1.255 109.815 1.479
202012 0.946 109.897 1.114
202103 1.517 111.754 1.757
202106 1.591 114.631 1.796
202109 1.500 115.734 1.677
202112 1.428 117.630 1.571
202203 1.330 121.301 1.419
202206 1.181 125.017 1.223
202209 0.902 125.227 0.932
202212 0.826 125.222 0.854
202303 0.636 127.348 0.646
202306 0.342 128.729 0.344
202309 0.203 129.860 0.202
202312 0.183 129.419 0.183

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


BioLine Rx  (NAS:BLRX) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


BioLine Rx Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of BioLine Rx's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


BioLine Rx (BioLine Rx) Business Description

Industry
Traded in Other Exchanges
Address
2 HaMa’ayan Street, Modi’in, ISR, 7177871
BioLine Rx Ltd is a pre-commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has an off-strategy, legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.

BioLine Rx (BioLine Rx) Headlines